Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Market Access

Multiple myeloma drug Blenrep backed for wider NHS use

 April 17, 2026

Pharmaphorum

The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.

Market AccessOncologyRead full story

Post navigation

Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions →
← Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com